Wortmannin渥曼青霉素 PI3K抑制剂 Polo-like kinase 1 (PLK1) Polo样激酶1抑制剂

Wortmannin 渥曼青霉素;SL-2052;PI3K抑制剂;Polo-like kinase 1 (PLK1) Polo样激酶1抑制剂; MLCK抑制剂;CAS:19545-26-7;

产品名称 产品编号 CAS NO. 规格
Wortmannin (25mM in DMSO) 渥曼青霉素 MZ0001-100UL 19545-26-7 100µl
Wortmannin (25mM in DMSO) 渥曼青霉素 MZ0001-500UL 19545-26-7 5×100µl
Wortmannin (Powder) 渥曼青霉素 MZ0001-10MG 19545-26-7 10mg
Wortmannin (Powder) 渥曼青霉素 MZ0001-25MG 19545-26-7 25mg
Wortmannin (Powder) 渥曼青霉素 MZ0001-50MG 19545-26-7 50mg

产品描述

渥曼青霉素(Wortmannin),分离自丝状真菌-绳状青霉(Penicillium funiculosum),是一种有效、不可逆且特异的磷脂酰肌醇3-激酶(PI3K)抑制剂(IC50=2~4nM)。具有良好的细胞膜渗透性,与PI3K的催化亚基结合,进而抑制酶的体内外活性。也能阻断自吞噬形成,有效抑制Polo样激酶1(PLK1)(IC50=5.8nM)。

在成纤维细胞中,渥曼青霉素废止PDGF介导的肌醇(3,4,5)P3的生成(IC50=5nM)。在豚鼠中性粒细胞中,抑制fMLP诱导的PIP3和超氧阴离子生成(IC50=50nM),以及磷脂酶D激活。在NGF处理的PC12细胞中,阻断轴突延伸。在大鼠嗜碱粒细胞性白血病细胞(RBL-2H3)中抑制IgE介导的组胺分泌。渥曼青霉素在更高的浓度下能抑制其他激酶,比如肌球蛋白轻链激酶MLCK(IC50=200 nM)和血小板活化因子诱导的MAP激酶活化(IC50=200~300nM)。

我司提供两种形式的渥曼青霉素(Wortmannin),一种以溶于DMSO的储存液形式提供,浓度为25mM,使用更方便;一种以冻干粉的形式提供,更经济实惠;

产品特性

1) CAS NO:19545-26-7

2) 化学名:(1S,6bR,9aS,11R,11bR)11-(Acetyloxy)-1,6b,7,8,9a,10,11,11b-octahydro-1-(methoxymethyl)-9a,11b- dimethyl-3H-furo[4,3,2-de]indeno[4,5,-h]-2-h]-2-benzopyran-3,6,9-trione

3) 同义名:SL-2052, Antibiotic SL-2052, KY 12420, Wartmannin

4) 分子式:C23H24O8

5) 分子量:428.43

6) 纯度:>98%

7) 溶解性(冻干粉):溶于DMSO(50mM),无水乙醇(5mM,温热助溶)

8) 化学结构图:

保存与运输方法

保存:冻干粉置于+ 4℃干燥保存,2年有效;-20℃干燥保存,3年有效;储存液置于-20℃保存,6个月有效;置于-80℃,12个月有效;

运输:冻干粉室温运输;储存液冰袋运输。

注意事项

1) 低温保存的本品需置于室温回温,低速离心至管底后,再开盖使用。对于储存液,在4℃、冰浴等较低温度情况下会凝固而粘在离心管管底、管壁或管盖内,可以25℃水浴温育片刻至全部融解后使用。

2) 本品对人体有毒,操作时请特别小心,并注意有效防护以避免直接接触人体或吸入体内。

3) 本品仅用作科研用途,不得用作临床诊断或治疗,不得用于食品或药品,绝对禁止用在人身上。

4) 为了您的安全和健康,请穿实验服并戴一次性手套操作。

储存液制备

 质量

溶剂体积

浓度

1mg 5mg 10mg

1mM

2.3341 mL 11.6705 mL 23.3410 mL
5mM 0.4668 mL 2.3341 mL

4.6682 mL

10mM 0.2334 mL 1.1671 mL

2.3341 mL

 

体内研究(动物模型):

动物模型(Animal Model):Tumor-bearing SCID mice (both s.c. and orthotopically implanted with human pancreatic adenocarcinoma cells PK1)

药物配制(Preparation):Wortmannin was dissolved at 0.4 mg/ml in DMSO, and diluted with 0.9% NaCl before use.

实验方法(Assay):A) In the first set of experiments, groups of tumor-bearing SCID mice (n = 4 each) were given single bolus injections of 0.7 mg/kg wortmannin via the tail vein and killed at various time points. B)  In a second series of experiments, groups of animals (n = 4 each) were injected i.v. with increasing doses of wortmannin (0.175, 0.35, and 0.7 mg/kg) and killed at 4 h. C) In a third series of experiments, tumor-bearing SCID mice were randomly assigned to four groups (n = 4 each). Each group was given i.v. bolus injections of either the drug vehicle (≤1% DMSO), 80 mg/kg of gemcitabine for 48 h, 0.7 mg/kg of wortmannin for 4 h, or 80 mg/kg of gemcitabine for 48 h and then 0.7 mg/kg wortmannin for 4 h.

 

体外研究(细胞实验):

动物模型(Animal Model):Hepatocytes from Wistar rats

药物配制(Preparation):Wortmannin was dissolved in DMSO at 2mM, and stored at -20℃ in the dark. Dilutions in 0.9% NaCl were prepared just before the start of each experiment. The final DMSO concentration in the incubation medium did not exceed 0.25 % (by vol.). This concentration of DMSO did not affect the processes that were tested.

实验方法(Assay):Electron micrographs of isolated rat hepatocytes that were incubated for 60 min (5 mg dry cells/ml) with 50μM vinblastin alone (A, B) or in the presence of 50μM vinblastin plus 100 nM wortmannin.

结果(Results):Autophagosomes could hardly be detected in cells that were incubated in the presence of 100 nM wortmannin (Fig. 3 C) compared to cells incubated under maximal autophagic conditions (Fig. 3 A and B).

相关产品

货号 名称 规格
MZ0001-10MG Wortmannin (Powder) 渥曼青霉素 10mg
MZ0002-10MG 3-Methyladenine (3-MA) 3-甲基腺嘌呤 10mg
MZ0003-10MG LY294002 10mg
MZ0201-10MG Rapamycin (Sirolimus) 雷帕霉素(西罗莫司) 10mg